Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health
There is now strong evidence to support the interest in using lactic acid bacteria (LAB)in particular, strains of lactococci and lactobacilli, as well as bifidobacteria, for the development of new live vectors for human and animal health purposes. LAB are Gram-positive bacteria that have been used for millennia in the production of fermented foods. In addition, numerous studies have shown that genetically modified LAB and bifodobacteria can induce a systemic and mucosal immune response against certain antigens when administered mucosally. They are therefore good candidates for the development of new mucosal delivery strategies and are attractive alternatives to vaccines based on attenuated pathogenic bacteria whose use presents health risks. This article reviews the most recent research and advances in the use of LAB and bifidobacteria as live delivery vectors for human and animal health.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Gut microbes - 14(2022), 1 vom: 01. Jan., Seite 2110821 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Levit, Romina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bifidobacteria |
|---|
| Anmerkungen: |
Date Completed 16.08.2022 Date Revised 10.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/19490976.2022.2110821 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344796388 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344796388 | ||
| 003 | DE-627 | ||
| 005 | 20231226023610.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/19490976.2022.2110821 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344796388 | ||
| 035 | |a (NLM)35960855 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Levit, Romina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2022 | ||
| 500 | |a Date Revised 10.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a There is now strong evidence to support the interest in using lactic acid bacteria (LAB)in particular, strains of lactococci and lactobacilli, as well as bifidobacteria, for the development of new live vectors for human and animal health purposes. LAB are Gram-positive bacteria that have been used for millennia in the production of fermented foods. In addition, numerous studies have shown that genetically modified LAB and bifodobacteria can induce a systemic and mucosal immune response against certain antigens when administered mucosally. They are therefore good candidates for the development of new mucosal delivery strategies and are attractive alternatives to vaccines based on attenuated pathogenic bacteria whose use presents health risks. This article reviews the most recent research and advances in the use of LAB and bifidobacteria as live delivery vectors for human and animal health | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Lactic acid bacteria | |
| 650 | 4 | |a bifidobacteria | |
| 650 | 4 | |a lactobacillus spp | |
| 650 | 4 | |a lactococcus lactis | |
| 650 | 4 | |a live delivery vectors | |
| 650 | 4 | |a mucosal vaccines | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Cortes-Perez, Naima G |e verfasserin |4 aut | |
| 700 | 1 | |a de Moreno de Leblanc, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Loiseau, Jade |e verfasserin |4 aut | |
| 700 | 1 | |a Aucouturier, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Langella, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a LeBlanc, Jean Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Bermúdez-Humarán, Luis G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gut microbes |d 2010 |g 14(2022), 1 vom: 01. Jan., Seite 2110821 |w (DE-627)NLM199892369 |x 1949-0984 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:2110821 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/19490976.2022.2110821 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 1 |b 01 |c 01 |h 2110821 | ||